^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Epratucyn (epratuzumab)

    i
    Associations
    News

    Trials

    Company:
    Gilead
    Drug class:
    CD22 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 (IntReALL SR 2010) (NCT01802814)
    Phase 3
    Charite University, Berlin, Germany
    Completed
    Last update posted :
    02/09/2024
    Initiation :
    05/01/2014
    Primary completion :
    07/31/2023
    Completion :
    07/31/2023
    CD22
    |
    CD22 expression
    |
    Epratucyn (epratuzumab)
    Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (NCT00301821)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Completed
    Last update posted :
    10/09/2019
    Initiation :
    01/01/2006
    Primary completion :
    10/01/2008
    Completion :
    04/01/2015
    CD20 • CD22
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epratucyn (epratuzumab)
    Multi-centric Study (CHEPRALL) (NCT01219816)
    Phase 2
    Nantes University Hospital
    Completed
    Last update posted :
    02/27/2018
    Initiation :
    11/01/2010
    Primary completion :
    11/01/2016
    Completion :
    11/01/2016
    CD22
    |
    CD22 expression
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • Epratucyn (epratuzumab)
    Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) (NCT00098839)
    Phase 2
    Children's Oncology Group
    Completed
    Last update posted :
    12/12/2017
    Initiation :
    02/01/2005
    Primary completion :
    04/01/2011
    Completion :
    04/01/2011
    CD22
    |
    CD22 expression
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Marqibo (vincristine liposomal) • Epratucyn (epratuzumab) • Neupogen (filgrastim) • cyclophosphamide intravenous • dexrazoxane
    S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT00945815)
    Phase 2
    Southwest Oncology Group
    Completed
    Last update posted :
    11/06/2017
    Initiation :
    09/01/2010
    Primary completion :
    03/01/2013
    Completion :
    08/01/2017
    CD22 • CD33 • CD4 • ANPEP
    |
    cytarabine • clofarabine • Epratucyn (epratuzumab)
    Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia (EPRALLO) (NCT02577094)
    Phase 1/2
    Nantes University Hospital
    Withdrawn
    Last update posted :
    01/19/2017
    Primary completion :
    01/01/2017
    Completion :
    01/01/2017
    CD22
    |
    CD22 expression
    |
    fludarabine IV • busulfan • Epratucyn (epratuzumab) • LymphoCide Y-90 (epratuzumab Y-90)
    Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma (NCT00553501)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Completed
    Last update posted :
    07/06/2016
    Initiation :
    03/01/2008
    Primary completion :
    07/01/2010
    Completion :
    07/01/2014
    CD20 • CD4
    |
    Rituxan (rituximab) • Epratucyn (epratuzumab)